

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JDH 京东健康

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

INSIDE INFORMATION

UNAUDITED UPDATE ON THE 2025 FIRST QUARTER

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

- JD Health continues to strengthen its position as “the first online marketplace for new and specialty drug launches.” During the first quarter of 2025, we debuted several innovative drugs online, including TALZENNA[®] (Talazoparib Tosylate Capsules) developed by Pfizer, Lysodren[®] (Mitotane Tablets) developed by Esteve, Diabegone[®] (Efsubaglutide Alfa Injection) developed by Innogen, and Longmu[®] Children’s Zibei Xuanfei Syrup by Jianmin Group, providing patients with a wider range of treatment options. JD Health also deepened its partnerships with various leading healthcare product companies, including By-Health, Yan Palace, and LifeStyles, to further develop synergies across product innovation, digital and intelligent supply chain, and precision marketing. At the Fifth JD Health Partner Conference, JD Health secured new product cooperation agreements with nearly 50 brands around the world in 2025. Through these collaborations, JD Health aims to help brands increase the exposure and conversion efficiency of new products, enrich and diversify product offerings for consumers, and jointly explore incremental growth opportunities in the health consumption market.

- During the first quarter of 2025, JD Health made significant progress in medical AI and continued to promote AI technology application in healthcare services, specialized disease diagnosis, and health management, among other areas. In January 2025, JD Health released the “AI Jingyi” system (AI京醫), enabling AI application across multiple online scenarios. This system provides doctors with intelligent diagnosis assistance and research support while also offering users personalized, professional healthcare services through AI-powered agents, such as AI doctors, AI pharmacists and AI nutritionists. In February 2025, JD Health open-sourced its “Jingyi Qianxun” (京醫千詢) LLM, making it the first fully open-source vertical large model in China’s medical industry. Our AI products have seen increasing acceptance and adoption among doctors at JD Health Online Hospital, with over 80% of consultations utilizing AI services and our AI nutritionist has achieved a service satisfaction rate of 91%.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue, operating income and profit of the Group for the three months ended March 31, 2025 together with comparative figures for the corresponding period of 2024:

	Three months ended March 31,		
	2025	2024	Change
	RMB’000	RMB’000	(%)
	(Unaudited)	(Unaudited)	
Revenue	16,645,156	13,267,397	25.5%
Operating income ⁽¹⁾	1,071,013	487,316	119.8%
Non-IFRS operating income ⁽²⁾	1,308,356	754,380	73.4%
Profit for the period	934,358	893,432	4.6%
Non-IFRS profit for the period ⁽³⁾	1,767,843	1,197,286	47.7%

(1) Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal.

(2) We define “non-IFRS operating income” as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

(3) We define “non-IFRS profit” as profit for the period, excluding share-based payment expenses, fair value changes for financial assets at fair value through profit or loss except for wealth management products, and tax effects on non-IFRS adjustments for the period. We exclude these items because they are non-operating in nature, not indicative of our core operating results and business outlook, or they do not generate any cash outflows.

The above information is based on the board (the “**Board**”) of directors (the “**Directors**”) of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Enlin Jin
Executive Director

Hong Kong, May 13, 2025

As of the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.